Clinical Trials Logo

Hepatitis, Chronic clinical trials

View clinical trials related to Hepatitis, Chronic.

Filter by:

NCT ID: NCT03038802 Not yet recruiting - Chronic Hepatitis b Clinical Trials

A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection

HBV003
Start date: September 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot study to determine the safety and efficacy of a novel adjuvanted hepatitis B virus (HBV) vaccine formulated as a potential therapeutic vaccine against chronic HBV infection. An ongoing human clinical trial of this HBV vaccine in a prophylactic setting has confirmed this vaccine to be more effective at inducing seroconversion as measured by development of Hepatitis B surface antibody (HBsAb) in poor responder subjects than the standard alum-adjuvanted HBV vaccine, providing promise that this new vaccine may also be able to induce HBV viral control and/or seroconversion in chronically infected subjects

NCT ID: NCT02950870 Not yet recruiting - Clinical trials for Chronic Hepatitis, C Virus

Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.

Start date: December 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determinate the AMH levels before and after antiviral therapy with Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in comparison with age-matched HCV-positive women not undergoing antiviral treatment.

NCT ID: NCT02865369 Not yet recruiting - Chronic Hepatitis C Clinical Trials

Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment

RELIF-C
Start date: September 2016
Phase: N/A
Study type: Observational [Patient Registry]

A study on regression of liver fibrosis assessed by transient elastography after Daclatasvir and Asunaprevir combined treatment in advanced fibrotic/cirrhotic patients with chronic hepatitis C genotype 1b Infection

NCT ID: NCT02793791 Not yet recruiting - Chronic Hepatitis B Clinical Trials

Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients

Start date: September 2016
Phase: N/A
Study type: Interventional

The aim of this study is to determine that for hepatic dysplastic nodules in patients with chronic hepatitis B, instead of enhanced follow-up, whether early minimally-invasive ablation therapy can reduce the incidence of hepatocellular carcinoma.

NCT ID: NCT02745132 Not yet recruiting - Hepatitis C Clinical Trials

Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)

CICHepC
Start date: June 2016
Phase: Phase 4
Study type: Interventional

The overall aim of this study is to evaluate the prevalence of cognitive impairments and brain anomalies in Chronic Hepatitis C infected individuals and to investigate likely changes in cognition and brain structure and function after treatment with Direct-acting Antivirals (DAAs).

NCT ID: NCT02691728 Not yet recruiting - Chronic Hepatitis C Clinical Trials

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

Start date: February 2016
Phase: Phase 4
Study type: Interventional

This study is evaluating the safety and efficacy of a 12 week treatment LDV/SOF FDC in patients with Chronic GT1 or GT4 HCV infection and autoimmune disease

NCT ID: NCT02617615 Not yet recruiting - Chronic Hepatitis C Clinical Trials

A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients

Start date: December 1, 2017
Phase: Phase 1
Study type: Interventional

A Phase 1, First-in-Human, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 in Healthy Volunteers and to Evaluate the Antiviral Activity of MB-110 in Hepatitis C Virus Infected Subjects

NCT ID: NCT02615639 Not yet recruiting - Chronic Hepatitis B Clinical Trials

A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB

CTHBVACADCHB
Start date: November 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The anti-virus effects is not satisfying in some of Chronic Hepatitis B(CHB) patients who have been on anti-Hepatitis B Virus (HBV) drugs therapy. Dendritic cell (DC) is critical in Hepatitis B Virus (HBV) specific immunity in the process of producing HBV promoter specific cytotoxic T cells (CTLs) and specific T helper cells (HTLs), however they are defective in CHB patients. Therefore, if it were going to remove HBV completely, it mainly depends if the body itself can produce enough HBV specific cytotoxic T cells (CTLs) and specific T helper cells (HTLs). Our research is to plus Hepatitis B Vaccine Activated-DCs therapy to CHB patients who have been on anti-HBV drugs but with poor effects, supposing to significantly improve anti-HBV efficacy, even to clean HBV from the patients.

NCT ID: NCT02589652 Not yet recruiting - Chronic Hepatitis B Clinical Trials

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Start date: October 2015
Phase: N/A
Study type: Observational

This is a multicenter, prospective cohort study to evaluate the efficacy and safety of sequential combination or switch therapy of pegylated interferon alfa-2a in chronic hepatitis B patients with low HBsAg and HBeAg titers after long-term entecavir therapy, and compared to those who continued on ETV therapy.

NCT ID: NCT02511496 Not yet recruiting - Chronic Hepatitis C Clinical Trials

Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia

Start date: September 2015
Phase: N/A
Study type: Observational [Patient Registry]

This study evaluates the current situation and follow-up of chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV) in Andalusia.